Ocular adnexal mantle cell lymphoma
Reviewed by Hetvi Bhatt

In this study the authors compare primary ocular adnexal (OA) mantle cell lymphoma (MCL) with initially systemic MCL occurring over a 30-year period. MCL is a rare form of lymphoma accounting for 5-11% of OA lymphomas and therefore knowledge of disease outcomes is limited. Patients were more typically male (5:1) and in their mid-60s. Patients presented with a mass, periorbital oedema or proptosis most commonly in both groups with the most common tumour location being the lacrimal gland (OA 57%, systemic 48%). Conjunctival involvement occurred more frequently in the primary OA MCL group (52% versus 19%). Survival rates were similar in the two groups and higher than previously reported (five-year DSS 87%). The authors also found that patients without disease recurrence most often received initial rituximab-based chemotherapy with autologous stem cell transplant than those with disease recurrence.

Clinical characteristics and outcomes of ocular adnexal mantle cell lymphoma.
Castillejo Becerra CM, Dalvin LA, Jevremovic D, et al.
ORBIT
2022;41(1):97-104.